Online inquiry

IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3062MR)

This product GTTS-WQ3062MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3062MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4614MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ880MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ11693MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ4814MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ12984MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ4873MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ7500MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ11759MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW